

Electronic Supplementary Information

Lewis acid triggered *N*-alkylation of sulfoximines through nucleophilic ring-opening of donor-acceptor cyclopropanes: synthesis of γ -sulfoximino malonic diesters

Satish G. More, ^{a, b} Gurunath Suryavanshi ^{*, a, b}

[†] *Chemical Engineering & Process Development Division, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pune, Maharashtra, India- 411008.*

[‡] *Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, INDIA- 201 002*


^{*} *Corresponding Author: Tel.: +91 20 25902547; Fax: +91 20 25902676;*

E-mail: gm.suryavanshi@ncl.res.in

Table of Contents

Sr. No.	Description	Page No.
1.	X-Ray crystallography of compound (3q)	S3-S5
2.	HPLC Data	S6-S7
3.	Copies of ¹ H, ¹³ C and ¹⁹ F NMR spectra of products	S8-S36
4.	Copy of ¹ H, ¹³ C NMR spectrum of γ -sulfoximino, α - bromo malonic diester (6)	S37
5.	Copy of ¹ H, ¹³ C NMR spectrum of synthetic utility of product 3a (7)	S38

1. X-Ray crystallography data of compound (3q)




(CCDC Deposition No.- 2114333)

Single-crystal diffraction analysis data were collected at 100 K with a BRUKER KAPPA APEX II CCD Duo diffractometer (operated at 1500 W power: 50 kV, 30 mA) using graphite monochromatic Mo K α radiation ($\lambda = 0.71073 \text{ \AA}$). In case of disordered solvent molecules, the contributions to the scattering arising from the disordered solvents in the crystal were removed by use of the utility SQUEEZE in the PLATON software package.

Sample preparation method for crystal growth

The 10 mg compound (3q) was taken in a 2 ml glass vial, 1ml Methanol solvent was added, and the vial was closed with the cotton plug. Kept it for 4 to 5 days for growing of crystal. Slow evaporation at room temperature in a dark place till crystals formed.



The thermal ellipsoid was drawn at the 50% probability level

checkCIF/PLATON report

Structure factors have been supplied for datablock(s) mo_sgmg_373_NEW_0m_a

THIS REPORT IS FOR GUIDANCE ONLY. IF USED AS PART OF A REVIEW PROCEDURE FOR PUBLICATION, IT SHOULD NOT REPLACE THE EXPERTISE OF AN EXPERIENCED CRYSTALLOGRAPHIC REFEREE.

No syntax errors found. CIF dictionary Interpreting this report

Datablock: mo_sgmg_373_NEW_0m_a

Bond precision: C-C = 0.0032 Å Wavelength=0.71073
Cell: a=41.083(6) b=41.083(6) c=8.1322(10)
alpha=90 beta=90 gamma=120
Temperature: 273 K

	Calculated	Reported
Volume	11887(4)	11887(4)
Space group	R -3	R -3 :H
Hall group	-R 3	-R 3
Moiety formula	C29 H29 N O7 S	?
Sum formula	C29 H29 N O7 S	C29 H29 N O7 S
Mr	535.59	535.59
Dx, g cm ⁻³	1.347	1.347
Z	18	18
Mu (mm ⁻¹)	0.171	0.171
F000	5076.0	5076.0
F000'	5080.79	
h, k, lmax	45, 45, 9	45, 45, 9
Nref	3839	3835
Tmin, Tmax	0.950, 0.966	
Tmin'	0.950	

Correction method= Not given

Data completeness= 0.999 Theta(max)= 23.363


R(reflections)= 0.0323(3390) wR2(reflections)=
0.0742(3835)

S = 0.603 Npar= 347

2. HPLC Data

1) HPLC of (±) 1a

Data File: E:\subhangi\SATISH REC. 12
Method: E:\subhangi\1IPA.met
Acquired: 1/25/2022 11:25:36 AM
Printed: 1/25/2022 11:46:50 AM




DAD: Signal A,
250 nm/Bw:4 nm
Results

Retention Time	Area	Area %	Height	Height %
11.920	14852158	49.30	764247	54.28
13.720	15276360	50.70	643785	45.72
15.280	83	0.00	26	0.00
Totals	30128601	100.00	1408058	100.00

2) HPLC of Chiral (1a)

Data File: E:\subhangi\SATISH CHIRAL FFF.dat
Method: E:\subhangi\1IPA.met
Acquired: 1/25/2022 4:04:40 PM
Printed: 1/25/2022 4:32:38 PM




DAD: Signal A,
250 nm/Bw:4 nm
Results

Retention Time	Area	Area %	Height	Height %
11.333	2420424	97.86	110400	98.08
13.000	52818	2.14	2160	1.92
Totals	2473242	100.00	112560	100.00



HPLC of (3a)

Data File: E:\subhangi\SATISH PRODUCT RCEMIC 1.dat
 Method: E:\subhangi\10IPA 90HEXANE.met
 Acquired: 1/25/2022 5:39:05 PM
 Printed: 1/25/2022 6:04:37 PM





DAD: Signal A, 250 nm/Bw:4 nm Results

Retention Time	Area	Area %	Height	Height %
0.247	3119	0.01	1307	0.12
14.387	12060902	49.59	578977	52.14
15.560	12256585	50.40	530080	47.74
Totals	24320606	100.00	1110364	100.00






Diethyl 2-(2-(4-methoxyphenyl)-2-(((4-methoxyphenyl) (oxo)(phenyl)-l6-sulfaneylidene)

amino) ethyl) malonate (3b)




Diethyl 2-(2-(4-methoxyphenyl)-2-((oxo(phenyl)(*p*-tolyl)-1 β -sulfaneylidene) amino) ethyl) malonate (3c)







AV-400-20210727-172201-11680.003.001.1r.esp


CHLOROFORM-d



AV-400-20210727-172201-11680.002.001.1r.esp





Diethyl 2-(((4-fluorophenyl) (oxo)(phenyl)-l6-sulfaneylidene) amino)-2-(4-methoxyphenyl) ethyl) malonate (3e)





AV-500-20210723-183431-7008.002.001.1r.esp

CHLOROFORM-d





Diethyl 2-(2-(((4-iodophenyl) (oxo)(phenyl)-16-sulfaneylidene) amino)-2-(4-methoxyphenyl) ethyl) malonate (3f)



AV-500-20210728-162247-7008.001.001.1r.esp CHLOROFORM-d




AV-400-20210728-160618-11801.001.001.1r.esp




Diethyl 2-(2-(4-methoxyphenyl)-2-((4-nitrophenyl)(oxo)(phenyl)-16-sulfaneylidene) amino) ethyl malonate (3g)




Diethyl 2-(2-(4-methoxyphenyl)-2-((oxo(phenyl)(*m*-tolyl)-16-sulfaneylidene) amino) ethyl) malonate (3h)




AV-500-20210726-113652-11801.002.001.1r.esp




AV-400-20210728-162312-7008.001.001.1r.esp





Diethyl 2-(2-(((3-fluorophenyl) (oxo)(phenyl)-l6-sulfaneylidene) amino)-2-(4-methoxyphenyl) ethyl) malonate (3i)







Diethyl 2-(2-(4-methoxyphenyl)-2-(((2-methoxyphenyl) (oxo)(phenyl)-16-sulfanylidene) amino) ethyl) malonate (3j)




Diethyl 2-(2-(4-methoxyphenyl)-2-(((2-nitrophenyl)(oxo)(phenyl)-16-sulfaneylidene)

amino) ethyl) malonate (3k)



Diethyl 2-(2-(((3,5-dimethylphenyl) (oxo)(phenyl)-l6-sulfaneylidene) amino)-2-(4-methoxyphenyl) ethyl) malonate (3l)

AV-400-20210614-204305-13120000.00400109RM-d





AV-400-20210614-204305-13120000.002.001.1r.esp

CHLOROFORM-d

169.45
169.29
158.74
150.42
145.59
136.00
129.71
129.60
128.06
127.69
124.40
123.83
113.78
113.54


77.32
77.00
76.68
61.30
61.25
56.40
55.15
49.41
44.62
38.98

13.99
13.96




Diethyl 2-(2-(4-methoxyphenyl)-2-((methyl(4-nitrophenyl) (oxo)-16-sulfaneylidene) amino) ethyl) malonate (3m)



AV-400-20210617-101335-7008.001.001.1r.esp CHLOROFORM-d




AV-400-20210617-101335-7008.002.001.1r.esp





Diethyl 2-(2-((benzyl(oxo)(phenyl)-l6-sulfaneylidene) amino)-2-(4-methoxyphenyl) ethyl) malonate (3n)








Diethyl 2-(2-((10-benzyl-5-oxido-10H-5λ4-phenothiazin-5-ylidene) amino)-2-(4-methoxyphenyl) ethyl) malonate (3p)



Diethyl 2-(2-(4-methoxyphenyl)-2-((10-oxido-9-oxo-9H-10λ4-thioxanthen-10-ylidene) amino) ethyl) malonate (3q)




Diethyl 2-(2-(4-methoxyphenyl)-2-((5-oxido-5 λ 4-dibenzo [b, d] thiophen-5-ylidene) amino) ethyl malonate (3r)





AV-400-20210901-095321-13120000.002.001.1r.esp

CHLOROFORM-d



Diethyl 2-(2-((oxodiphenyl-l6-sulfaneylidene) amino)-2-phenylethyl) malonate (5a)



Diethyl 2-(2-(4-(methylthio) phenyl)-2-((oxodiphenyl-16-sulfaneylidene) amino) ethyl) malonate (5b)




AV-400-20210910-162310-11801.001.001.1r.esp

TMS

8.14
8.12
7.96
7.94
7.77
7.75
7.53
7.51
7.50
7.38
7.36

4.36
4.20
4.19
4.17
4.15
4.12
4.10
4.08
3.79
3.39
2.38
2.37
2.36
2.35
1.28
1.26
1.24
1.22
1.20
1.18

0.00





AV-400-20210910-162310-11801.002.001.1r.esp

CHLOROFORM-d

169.53
169.26
152.88
146.82
140.42
140.07
132.69
132.59
129.18
128.97
128.42
128.38
127.61
123.50



77.32
77.00
76.68
61.33
55.96
48.97
39.35
13.94



Diethyl 2-(2-(4-nitrophenyl)-2-((oxodiphenyl-16-sulfanylidene) amino) ethyl) malonate (5c)



AV-400-20210831-101110-13120000.001.001.1r.esp

TMS



AV-500-20210830-170515-7008.002.001.1r.esp


CHLOROFORM-d



Diethyl 2-(2-(4-chlorophenyl)-2-((oxodiphenyl-16-sulfaneylidene) amino) ethyl) malonate (5d)


AV-400-20210907-163521-7008.001.001.1r.esp

TMS





AV-400-20210907-163521-7008.002.001.1r.esp

CHLOROFORM-d




Diethyl 2-(2-((oxodiphenyl-16-sulfanylidene) amino)-2-(*o*-tolyl) ethyl) malonate (5e)

AV-500-20210830-094938-11801.001.D CDCl₃ DMSO-d₆




AV-500-20210901-095343-13120000.002.001.1r.esp

CHLOROFORM-d




Diethyl 2-(2-(3,4-dimethoxyphenyl)-2-((oxodiphenyl-16-sulfaneylidene) amino) ethyl) malonate (5f)



AV-400-20210825-100942-11801.001.001.10r1
CHLOROFORM-d




AV-400-20210825-100942-11801.002.001.1r.esp




Diethyl 2-(2-(furan-2-yl)-2-((oxodiphenyl-16-sulfaneylidene) amino) ethyl) malonate (5g)



Diethyl 2-(2-((oxodiphenyl-l6-sulfaneylidene) amino)-2-(thiophen-2-yl) ethyl) malonate
(5h)






4. ¹H, and ¹³C NMR spectrum of γ -sulfoximino, α - bromo malonic diester (6)


AV-500-20210825-101005-11801.001.001.1r.esp

TMS





AV-500-20210825-101005-11801.002.001.1r.esp

CHLOROFORM-d



Diethyl 2-bromo-2-(2-(4-methoxyphenyl)-2-((oxo(phenyl)(*p*-tolyl)-16-sulfaneylidene) amino) ethyl) malonate (6)

5. ¹H, and ¹³C NMR spectrum of synthetic utility of product 3a (7)



Diethyl 2-allyl-2-(2-(4-methoxyphenyl)-2-((oxodiphenyl-l6-sulfaneylidene) amino) ethyl) malonate (7)